Literature DB >> 8120398

Induction of macrophage growth by advanced glycation end products of the Maillard reaction.

S Yui1, T Sasaki, N Araki, S Horiuchi, M Yamazaki.   

Abstract

We previously showed that negatively-charged phospholipids, acetylated low density lipoprotein (LDL) and oxidized LDL, which are known to be taken up by macrophages via the scavenger receptor for modified LDLs, were able to induce the growth of peripheral macrophages in vitro. The present study demonstrated the macrophage growth-stimulating activity of the ligands for another macrophage receptor for advanced glycation end products (AGE) of the Maillard reaction. Experiments with murine macrophages showed that significant cell growth was induced by AGE-modified proteins such as bovine serum albumin (AGE-BSA) and AGE-human hemoglobin. The capacity of AGE-BSA to induce macrophage growth was completely blocked when cells were cultured with the mAb against granulocyte/macrophage CSF (GM-CSF). Moreover, PCR analysis revealed that AGE-BSA induced the expression of mRNA of GM-CSF. These data suggest that the macrophage AGE receptor may play an active role not only in phagocytic elimination of AGE-proteins but also induction of the growth of macrophages.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120398

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis.

Authors:  T Matsuse; E Ohga; S Teramoto; M Fukayama; R Nagai; S Horiuchi; Y Ouchi
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

Review 2.  Mechanisms of distal axonal degeneration in peripheral neuropathies.

Authors:  Christopher R Cashman; Ahmet Höke
Journal:  Neurosci Lett       Date:  2015-01-21       Impact factor: 3.046

Review 3.  Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis.

Authors:  Sherman S Leung; Josephine M Forbes; Danielle J Borg
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

4.  Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins.

Authors:  M E Westwood; P J Thornalley
Journal:  J Protein Chem       Date:  1995-07

5.  Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries.

Authors:  Evanthia Diamanti-Kandarakis; Christina Piperi; Efstratios Patsouris; Penelope Korkolopoulou; Dimitrios Panidis; Leszek Pawelczyk; Athanasios G Papavassiliou; Antoni J Duleba
Journal:  Histochem Cell Biol       Date:  2007-01-05       Impact factor: 2.531

6.  Electrophoretic pattern changes in macrophage cell lines due to culture in protein-free medium.

Authors:  J G Bruno; E Holwitt; J L Kiel
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.723

7.  Characterization of the growth-inhibitory and apoptosis-inducing activities of a triterpene saponin, securioside B against BAC1.2F5 macrophages.

Authors:  Satoru Yui; Tomoya Kudo; Kazumi Hodono; Yoshihiro Mimaki; Minpei Kuroda; Yutaka Sashida; Masatoshi Yamazaki
Journal:  Mediators Inflamm       Date:  2003-06       Impact factor: 4.711

8.  Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction.

Authors:  Danielle J Borg; Felicia Y T Yap; Sahar Keshvari; David G Simmons; Linda A Gallo; Amelia K Fotheringham; Aowen Zhuang; Robyn M Slattery; Sumaira Z Hasnain; Melinda T Coughlan; Phillip Kantharidis; Josephine M Forbes
Journal:  Islets       Date:  2017-12-22       Impact factor: 2.694

9.  Advanced Glycation End Products Enhance Murine Monocyte Proliferation in Bone Marrow and Prime Them into an Inflammatory Phenotype through MAPK Signaling.

Authors:  Xian Jin; Liang Liu; Yaping Zhang; Yin Xiang; Guizhi Yin; Yi Lu; Ludong Shi; Jian Dong; Chengxing Shen
Journal:  J Diabetes Res       Date:  2018-03-22       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.